June 21, 2023 — We’re packing our bag for San Diego and the 83rd Scientific Sessions of the American Diabetes Association, which starts on Friday. This is not a meeting that has been a regular habit for ConscienHealth. But this year it seems ADA2023 will be another milestone in the ongoing diabesity merger. That almost too clever term first […]
April 3, 2023 — This is a merger that has taken decades – the merger of obesity and diabetes. Ethan Sims first coined the term diabesity in 1973. Even five decades ago, the coincidence of diabetes and obesity was unmistakable, but the standards of care for obesity and diabetes did not reflect the recognition of obesity as anything other […]
February 23, 2018 — Wachet auf! As if the clues were not already present, an announcement yesterday makes it plain. Competitors in the sleepy diabesity market had best wake up. The first ever oral GLP-1 agonist for diabetes and obesity – semaglutide – is looking good in clinical trials. That means everyone else had better get serious about innovation. Or risk becoming […]
August 18, 2017 — Call us superstitious. The hopes for a new diabesity drug – semaglutide – are growing higher. And to us, that’s a good news, bad news story. The high hopes are coming from good clinical results for this new GLP-1 agonist in a head-to-head comparison with dulaglutide from Eli Lilly. Dulaglutide is a GLP-1 activator that’s already on […]
